http://hdl.handle.net/1765/3681
http://dx.doi.org/10.1016/S0264-410X(98)00498-8
pubmed: 10418922
scopus: cited 92 times
web of science: cited 92 times
http://dx.doi.org/10.1016/S0264-410X(98)00498-8
pubmed: 10418922
scopus: cited 92 times
web of science: cited 92 times
Vaccination with Rev and Tat against AIDS.
1999-06-04
Article
volume 17, issue 20-21 pp 2713-2714.
| Related Files |
|---|
|
Redirect to Publisher's version
(Publisher's version.url.txt, 47 bytes) |
Repository contains one additional file which is not publicly available
Intro: More than 15 years after the discovery of HIV-1 as the causative agent of AIDS, and numerous attempts to develop a vaccine, it has become clear that the efficacy of the currently considered HIV-1 vaccine candidates will generally be limited. This is at least in part due to the relative resistance of so-called primary HIV strains to neutralization by HIV-1 envelope specific antibodies: even the most potent HIV-1 neutralizing antibodies failed to provide protection in in vivo models, at concentrations that can be maintained for longer periods in human vaccinees.
Keywords
- Animals
- Human
- Macaca fascicularis
- Vaccination
- Pilot Projects
- Vaccines, Synthetic/*immunology
- Viral Vaccines/*immunology
- 0 (Viral Vaccines)
- Acquired Immunodeficiency Syndrome/*prevention & control
- 0 (Vaccines, Synthetic)
- 0 (Gene Products, rev)
- 0 (Gene Products, tat)
- Gene Products, rev/*immunology
- Gene Products, tat/*immunology
- T-Lymphocytes, Cytotoxic/immunology
